Ref. Ares(2019)36522 - 07/71/2019

Please find below some information on the activities of the EURIPID Collaboration.

Please note that the actual website of the Collaboration is not publicly accessible but we are happy to provide you with some key information on our work and partnership. The undertaking receives some co-funding from European Commission, as outlined.

Grant Name: Supporting Member States voluntary cooperation in the area of pricing through the EURIPID Collaboration — EURIPID
Call: HP-PJ-2018
Number: 826652
Start Date: 2019-02-01
End Date: 2022-01-31
Max. EU Contribution: EUR 299,994.00

The consortium acting on behalf of the EURIPID Collaboration under this grant consists of:

  • NATIONAL INSTITUTE OF HEALTH INSURANCE FUND MANAGEMENT (NEAK), Hungary
  • AUSTRIAN PUBLIC HEALTH INSTITUTE (GÖG), Austria
  • STATE INSTITUTE FOR DRUG CONTROL (SÚKL), The Czech Republic
  • DENTAL AND PHARMACEUTICAL BENEFITS AGENCY (TLV), Sweden
  • NORWEGIAN MEDICINES AGENCY (NOMA), Norway
  • PHARMECA a. s., The Czech Republic

EURIPID Collaboration is a voluntary and strictly non-profit cooperation between mostly European countries on building up and maintaining a database with information on national prices and pricing regulations of medicinal products in a standardized format.

This online database is currently exclusively available for national competent authorities for pricing and reimbursement of medicinal products, who agreed on the rules of the Collaboration and who participate actively. It contains data on official prices of publicly reimbursed, mainly out-patient medicinal products that are published by national authorities in line with the Transparency Directive 89\105\EC.

The database has been of great value to the authorities in the past years aiding them in their decision making duties. With the expanded funding opportunity from the EC, the EURIPID consortium will be able to achieve even more additional value for the users.

Activities under the Grant will be the voluntary cooperation between the national authorities

  • by further expand the information provision on the existence of managed entry agreements, prices and sales volumes of reimbursable medicinal products,
  • by enhancing the services for users and also to the general public and
  • by strengthening the cooperation in the field of pricing of medicinal products (e.g. establishing a Dialogue Platform with stakeholders).

The Collaboration will enhance public interfaces of the EURIPID website and establish regular newsletters so that more information about its activity will be shared with the general public; the spreading of the recommendations of the technical Guidance Document on External Reference Pricing developed in the previous grant period; the extension of the data content of the database to non-reimbursed but regulated priced products.

26+ European Countries participating

10 000 000+ Price References of medicinal products

24h online availability of database

9+ Years of Experience of project partners

2009 First financial contribution by EU

60% funding by national pricing and reimbursement authorities

 

Stakeholders at EU level that will be involved in process are

  • National competent authorities for pricing and reimbursement of medicinal products
  • Pharmaceutical Industry Associations
  • Patients’ Organisations and NGOs
  • Third Party Payers
  • Doctor’s Association
  • Association of Distributors

The content of this website represents the view of the EURIPID consortium members only and is their sole responsibility. It can not be considered to reflect the views of the European Commission and/or the Consumer Health Agriculture and Food Executive Agency (CHAFEA) or any other body established within the remit of the Institutions of the European Union. The European Commission and the CHAFEA do not accept any responsibility for use that may be made of the information it contains.